LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

455.65 -6.47

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

427.47

Max

490.62

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
Winstmarge	-39.75
Werknemers	528
EBITDA	-68M -106M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+44.78% upside

Dividenden
By Dow Jones
Volgende Winsten	19 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.4B 11B
Vorige openingsprijs	462.12
Vorige sluitingsprijs	455.65

Nieuwssentiment

By Acuity

50%

165 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 feb 2026, 22:31 UTC

Winsten

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb 2026, 22:18 UTC

Winsten

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb 2026, 22:11 UTC

Winsten

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb 2026, 21:52 UTC

Winsten

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb 2026, 23:56 UTC

Marktinformatie

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb 2026, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 feb 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb 2026, 23:34 UTC

Marktinformatie

Winsten

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb 2026, 23:33 UTC

Marktinformatie

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb 2026, 23:32 UTC

Marktinformatie

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb 2026, 22:45 UTC

Winsten

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb 2026, 22:44 UTC

Marktinformatie

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb 2026, 22:37 UTC

Winsten

Nutrien 4Q EPS $1.18 >NTR.T

18 feb 2026, 22:37 UTC

Winsten

Nutrien 4Q Sales $5.34B >NTR.T

18 feb 2026, 22:35 UTC

Winsten

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb 2026, 22:35 UTC

Winsten

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb 2026, 22:30 UTC

Winsten

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb 2026, 22:29 UTC

Winsten

Kinross Gold 4Q EPS 75c >K.T

18 feb 2026, 22:22 UTC

Winsten

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb 2026, 22:22 UTC

Marktinformatie

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb 2026, 22:16 UTC

Winsten

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb 2026, 22:05 UTC

Winsten

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb 2026, 22:03 UTC

Winsten

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb 2026, 22:02 UTC

Winsten

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb 2026, 22:02 UTC

Winsten

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb 2026, 22:02 UTC

Winsten

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb 2026, 22:00 UTC

Winsten

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb 2026, 22:00 UTC

Winsten

Kinross Gold 4Q Sales $2.02B >KGC

18 feb 2026, 21:56 UTC

Winsten

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

44.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 705.56 USD 44.78%

Hoogste 964 USD

Laagste 570 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

165 / 351 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.